Direkt zum Inhalt
Merck
  • The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages.

The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages.

PloS one (2014-04-17)
Maria Ruweka Fernando, Jose Luis Reyes, Jordan Iannuzzi, Gabriella Leung, Derek Mark McKay
ZUSAMMENFASSUNG

Macrophages are important innate immune cells that are associated with two distinct phenotypes: a pro-inflammatory (or classically activated) subset with prototypic macrophage functions such as inflammatory cytokine production and bactericidal activity, and an anti-inflammatory (or alternatively activated (AAM)) subset linked with wound healing and tissue repair processes. In this study, we examined the effect of interlukein-6 on human and murine macrophage polarization. The results indicate that despite being commonly associated with pro-inflammatory functions and being implicated in the pathogenesis/pathophysiology of numerous inflammatory diseases, interleukin-6 can enhance the polarization of AAMs, based on increased expression of hallmark markers: arginase-1, Ym1 and CD206; this effect required the AAM differentiating cytokines, IL-4 and IL-13. Co-treatment of AAMs with IL-6 resulted in spontaneous release of IL-10, suppressed LPS-induced nitric oxide production and inhibited cytokine production by activated CD4+ T cells - immunoregulatory features not observed in the 'parent' IL-4+IL-13-induced AAM. The effect of IL-6 required signal transducer and activator of transcription (STAT)-3, was partially dependent on up-regulation of the IL4Rα chain, and was independent of autocrine IL-10. In the presence of IFNγ, IL-6 promoted the production of IL-1β and TNFα suggesting that this cytokine can enhance the phenotype to which a macrophage has committed. This finding may explain the pleiotrophic nature of IL-6, where it is associated with the perpetuation and enhancement of disease in inflammatory situations, but is also necessary for resolution of inflammation and adequate wound healing to occur in others. Thus, the potential benefit of IL-6 in promoting an AAM, with its' anti-inflammatory and wound healing ability, may need to be considered in immunotherapies aimed at in vivo modulation or inhibition of IL-6.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
N-(1-Naphthyl)ethylendiamin -dihydrochlorid, ACS reagent, >98%
Sigma-Aldrich
N-(1-Naphthyl)ethylendiamin -dihydrochlorid, ≥98%
Sigma-Aldrich
Sulfanilamid, ≥98%
Supelco
Sulfanilamid Schmelzpunktstandard, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Mouse Tumor Necrosis Factor α ELISA Kit, for serum, plasma and cell culture supernatant
USP
Sulfanilamid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Rat Tumor Necrosis Factor α ELISA Kit, for serum, plasma and cell culture supernatant
Sigma-Aldrich
Sulfanilamid, puriss. p.a., ≥98% (calc. to the dried substance)
Sigma-Aldrich
Rat Tumor Necrosis Factor α ELISA Kit, for cell and tissue lysates
Supelco
N-(1-Naphthyl)ethylendiamin -dihydrochlorid, for determination of sulfonamide and nitrite, ACS reagent, ≥98%
Supelco
Sulfanilamid, VETRANAL®, analytical standard
USP
Sulfanilamid, United States Pharmacopeia (USP) Reference Standard
Sulfanilamid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Bovine TNFα / Tumor Necrosis Factor alpha ELISA Kit, for serum, plasma and cell culture supernatants
Sigma-Aldrich
MISSION® esiRNA, targeting human STAT3
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Stat3